, Annexe 3 : Gènes pour lesquels deux mutations ou plus ont été identifiées entre des échantillons différents
, Voies de régulation biologiques des ostéosarcomes, vol.4, p.39
The epidemiology of osteosarcoma, Cancer Treat. Res, vol.152, pp.3-13, 2009. ,
Osteosarcoma: A Meta-Analysis and Review of the Literature, The American Journal of Orthopedics, vol.44, pp.547-553, 2015. ,
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution, Cancer, vol.106, pp.1154-1161, 2006. ,
Tumor size as a predictor of outcome in pediatric non-metastatic osteosarcoma of the extremity, Pediatr Blood Cancer, vol.43, pp.723-728, 2004. ,
A review of clinical and molecular prognostic factors in osteosarcoma, J. Cancer Res. Clin. Oncol, vol.134, pp.281-297, 2008. ,
Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute, Oncol. Rep, vol.9, pp.171-175, 2002. ,
Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database, Cancer Epidemiology, vol.39, pp.593-599, 2015. ,
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols, J. Clin. Oncol, vol.20, pp.776-790, 2002. ,
Prognostic factors in osteosarcoma: a critical review, J. Clin. Oncol, vol.12, pp.423-431, 1994. ,
DOI : 10.1200/jco.1994.12.2.423
Prognostic factors in localized extremity osteosarcoma: a systematic review, Eur J Surg Oncol, vol.35, pp.1030-1036, 2009. ,
DOI : 10.1016/j.ejso.2009.01.011
Classification, imaging, biopsy and staging of osteosarcoma., Classification, imaging, biopsy and staging of osteosarcoma, Indian J Orthop, vol.48, pp.238-246, 2014. ,
Anatomic and Histologic Variants, American Journal of Clinical Pathology, vol.125, pp.555-581, 2006. ,
Rôle du pathologiste dans la prise en charge des tumeurs osseuses primitives malignes : ostéosarcomes et tumeurs de la famille Ewing après traitement néoadjuvant, Annales de Pathologie, vol.31, pp.455-465, 2011. ,
DOI : 10.1016/j.annpat.2011.10.009
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity, N. Engl. J. Med, vol.314, pp.1600-1606, 1986. ,
Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study, Clin. Orthop. Relat. Res, vol.8, p.14, 1991. ,
SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients, European Journal of Cancer, vol.43, pp.752-761, 2007. ,
Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy, J Bone Joint Surg Br, vol.84, pp.88-92, 2002. ,
DOI : 10.1302/0301-620x.84b1.0840088
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report, J. Clin. Oncol, vol.18, pp.4016-4027, 2000. ,
Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial, J Clin Oncol, vol.33, pp.2279-2287, 2015. ,
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial, Lancet Oncol, vol.17, pp.1396-1408, 2016. ,
Future directions in the treatment of osteosarcoma, Curr. Opin. Pediatr, vol.28, pp.26-33, 2016. ,
Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma, Cancer, vol.92, pp.2181-2189, 2001. ,
Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up, J. Natl. Cancer Inst, vol.100, pp.1771-1779, 2008. ,
Molecular genetics of osteosarcoma, Bone, 2016. ,
Translational biology of osteosarcoma, Nat Rev Cancer, vol.14, pp.722-735, 2014. ,
Mutational heterogeneity in cancer and the search for new cancerassociated genes, Nature, vol.499, pp.214-218, 2013. ,
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma, Proc Natl Acad Sci U S A, vol.111, pp.5564-73, 2014. ,
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency, Nat Commun, vol.6, 2015. ,
Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations, JCO, vol.35, pp.11019-11019, 2017. ,
PathScore: a web tool for identifying altered pathways in cancer data, Bioinformatics, vol.32, pp.3688-3690, 2016. ,
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma, Cell Rep, vol.7, pp.104-112, 2014. ,
Next-generation sequencing of RNA and DNA isolated from paired freshfrozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue, PLoS ONE, vol.9, p.98187, 2014. ,
Effects of formalin fixation, paraffin embedding, and time of storage on DNA preservation in brain tissue: a BrainNet Europe study, Brain Pathol, vol.17, pp.297-303, 2007. ,
DNA degrades during storage in formalin-fixed and paraffin-embedded tissue blocks, Virchows Arch, vol.471, pp.491-500, 2017. ,
Whole-exome analysis in osteosarcoma to identify a personalized therapy, Oncotarget, vol.8, pp.80416-80428, 2017. ,
Genome structural variation discovery and genotyping, Nat Rev Genet, vol.12, pp.363-376, 2011. ,
The landscape of somatic copy-number alteration across human cancers, Nature, vol.463, pp.899-905, 2010. ,
Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study, Cancer, vol.118, pp.1856-1867, 2012. ,
The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer, Expert Rev Anticancer Ther, vol.16, pp.383-390, 2016. ,
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing, Ann. Oncol, vol.25, pp.423-428, 2014. ,
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial, Cancer Discov, vol.7, pp.586-595, 2017. ,
, Meeting Library | Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfilER Study, p.28, 2017.
BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel, Br. J. Dermatol, vol.168, pp.700-707, 2013. ,
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, Nature, vol.483, pp.100-103, 2012. ,
Systems biology of the metabolic network regulated by the Akt pathway, Biotechnol. Adv, vol.30, pp.131-141, 2012. ,
Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells, Gynecologic Oncology, vol.128, pp.335-343, 2013. ,
Role of RANK and Akt1 activation in human osteosarcoma progression: A clinicopathological study, Exp Ther Med, vol.13, pp.2862-2866, 2017. ,
PRKDC regulates chemosensitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, Oncol. Rep, vol.37, pp.3536-3542, 2017. ,
Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63, Tumour Biol, vol.36, pp.9365-9372, 2015. ,
JAK/STAT signaling in hematological malignancies, Oncogene, vol.32, pp.2601-2613, 2013. ,
Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma, Mol Med Rep, vol.12, pp.498-502, 2015. ,
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N. Engl. J. Med, vol.372, pp.2509-2520, 2015. ,
Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade, Science, vol.357, pp.409-413, 2017. ,